ArchPoint Investors’s Recursion Pharmaceuticals RXRX Stock Holding History

ArchPoint Investors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,047,386	Closed	-$8.01M	–	56
2023 Q3	$8.01M	Sell	1,047,386 -67,240	-6%	-$671K	3.06%	6
2023 Q2	$8.33M	Hold	1,114,626	–	–	3.22%	7
2023 Q1	$7.43M	Hold	1,114,626	–	–	3.23%	9
2022 Q4	$8.59M	Sell	1,114,626 -1,500	-0.1%	-$14.7K	4.07%	6
2022 Q3	$11.9M	Sell	1,116,126 -151,304	-12%	-$1.53M	4.85%	4
2022 Q2	$10.3M	Hold	1,267,430	–	–	4.09%	5
2022 Q1	$9.07M	Buy	1,267,430 +12,000	+1%	+$128K	3.13%	7
2021 Q4	$21.5M	Buy	+1,255,430	New	+$23.6M	6.38%	3

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

ArchPoint Investors's RXRX Position: Q4 2023 in Review

ArchPoint Investors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 1,047,386 shares — an estimated $8.01M sold.

ArchPoint Investors first reported a position in RXRX in Q4 2021 and held it in 8 quarters. The position peaked at $21.5M in Q4 2021. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

ArchPoint Investors reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
ArchPoint Investors sold 1,047,386 Recursion Pharmaceuticals shares in Q4 2023, an estimated $8.01M.
ArchPoint Investors first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 8 quarters.
ArchPoint Investors's Recursion Pharmaceuticals position peaked at $21.5M in Q4 2021.
199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on ArchPoint Investors's 13F filing for Q4 2023, filed 13 Feb 2024.